Literature DB >> 35052707

Discovery Potent of Thiazolidinedione Derivatives as Antioxidant, α-Amylase Inhibitor, and Antidiabetic Agent.

Manal Y Sameeh1, Manal M Khowdiary1,2, Hisham S Nassar3,4, Mahmoud M Abdelall4, Suliman A Alderhami3, Ahmed A Elhenawy3,4.   

Abstract

This work aimed to synthesize safe antihyperglycemic derivatives bearing thiazolidinedione fragment based on spectral data. The DFT theory discussed the frontier molecular orbitals (FMOs), chemical reactivity of compounds, and molecular electrostatic potential (MEP) to explain interaction between thiazolidinediones and the biological receptor. α-amylase is known as the initiator-hydrolysis of the of polysaccharides; therefore, developing α-amylase inhibitors can open the way for a potential diabetes mellitus drug. The molecular docking simulation was performed into the active site of PPAR-γ and α-amylase. We evaluated in vitro α-amylase's potency and radical scavenging ability. The compound 6 has the highest potency against α-amylase and radical scavenging compared to the reference drug and other members. They have been applied against anti-diabetic and anti-hyperlipidemic activity (in vivo) based on an alloxan-induced diabetic rat model during a 30-day treatment protocol. The most potent anti hyperglycemic members are 6 and 11 with reduction percentage of blood glucose level by 69.55% and 66.95%, respectively; compared with the normal control. Other members exhibited moderate to low anti-diabetic potency. All compounds showed a normal value against the tested biochemical parameters (CH, LDL, and HDL). The ADMET profile showed good oral bioavailability without any observed carcinogenesis effect.

Entities:  

Keywords:  anti-diabetic; antioxidant; molecular docking; thiazolidinedione

Year:  2021        PMID: 35052707      PMCID: PMC8773338          DOI: 10.3390/biomedicines10010024

Source DB:  PubMed          Journal:  Biomedicines        ISSN: 2227-9059


  45 in total

Review 1.  The PPARs: from orphan receptors to drug discovery.

Authors:  T M Willson; P J Brown; D D Sternbach; B R Henke
Journal:  J Med Chem       Date:  2000-02-24       Impact factor: 7.446

2.  Pancreatic anticancer activity of a novel geranylgeranylated coumarin derivative.

Authors:  Tehsina Devji; Claire Reddy; Christina Woo; Suresh Awale; Shigetoshi Kadota; Dora Carrico-Moniz
Journal:  Bioorg Med Chem Lett       Date:  2011-08-08       Impact factor: 2.823

Review 3.  The role of ligand efficiency metrics in drug discovery.

Authors:  Andrew L Hopkins; György M Keserü; Paul D Leeson; David C Rees; Charles H Reynolds
Journal:  Nat Rev Drug Discov       Date:  2014-02       Impact factor: 84.694

Review 4.  Recent advances of intervention to inhibit progression of carotid intima-media thickness in patients with type 2 diabetes mellitus.

Authors:  Hiroki Yokoyama; Naoto Katakami; Yoshimitsu Yamasaki
Journal:  Stroke       Date:  2006-08-03       Impact factor: 7.914

5.  IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045.

Authors:  N H Cho; J E Shaw; S Karuranga; Y Huang; J D da Rocha Fernandes; A W Ohlrogge; B Malanda
Journal:  Diabetes Res Clin Pract       Date:  2018-02-26       Impact factor: 5.602

Review 6.  Therapeutic journey of 2,4-thiazolidinediones as a versatile scaffold: An insight into structure activity relationship.

Authors:  Mohd Javed Naim; Md Jahangir Alam; Shujauddin Ahmad; Farah Nawaz; Neelima Shrivastava; Meeta Sahu; Ozair Alam
Journal:  Eur J Med Chem       Date:  2017-02-20       Impact factor: 6.514

7.  Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial.

Authors:  Juan Pablo Frias; Michael A Nauck; Joanna Van; Mark E Kutner; Xuewei Cui; Charles Benson; Shweta Urva; Ruth E Gimeno; Zvonko Milicevic; Deborah Robins; Axel Haupt
Journal:  Lancet       Date:  2018-10-04       Impact factor: 79.321

8.  Acarbose for the prevention of Type 2 diabetes, hypertension and cardiovascular disease in subjects with impaired glucose tolerance: facts and interpretations concerning the critical analysis of the STOP-NIDDM Trial data.

Authors:  J-L Chiasson; R G Josse; R Gomis; M Hanefeld; A Karasik; M Laakso
Journal:  Diabetologia       Date:  2004-05-26       Impact factor: 10.122

9.  Antihyperlipidemic and antiperoxidative effect of Diasulin, a polyherbal formulation in alloxan induced hyperglycemic rats.

Authors:  Ramalingam Saravanan; Leelavinothan Pari
Journal:  BMC Complement Altern Med       Date:  2005-06-22       Impact factor: 3.659

10.  Synthesis, comparative docking, and pharmacological activity of naproxen amino acid derivatives as possible anti-inflammatory and analgesic agents.

Authors:  Ahmed A Elhenawy; L M Al-Harbi; Gaber O Moustafa; M A El-Gazzar; Rehab F Abdel-Rahman; Abd Elhamid Salim
Journal:  Drug Des Devel Ther       Date:  2019-05-24       Impact factor: 4.162

View more
  3 in total

Review 1.  Heterocyclic compounds as a magic bullet for diabetes mellitus: a review.

Authors:  Umme Farwa; Muhammad Asam Raza
Journal:  RSC Adv       Date:  2022-08-16       Impact factor: 4.036

2.  Synthesis, biological evaluation and in-silico ADME studies of novel series of thiazolidin-2,4-dione derivatives as antimicrobial, antioxidant and anticancer agents.

Authors:  Harsh Kumar; Davinder Kumar; Pradeep Kumar; Suresh Thareja; Minakshi Gupta Marwaha; Umashanker Navik; Rakesh Kumar Marwaha
Journal:  BMC Chem       Date:  2022-09-15

Review 3.  Thiazolidin-2,4-Dione Scaffold: An Insight into Recent Advances as Antimicrobial, Antioxidant, and Hypoglycemic Agents.

Authors:  Harsh Kumar; Navidha Aggarwal; Minakshi Gupta Marwaha; Aakash Deep; Hitesh Chopra; Mohammed M Matin; Arpita Roy; Talha Bin Emran; Yugal Kishore Mohanta; Ramzan Ahmed; Tapan Kumar Mohanta; Muthupandian Saravanan; Rakesh Kumar Marwaha; Ahmed Al-Harrasi
Journal:  Molecules       Date:  2022-10-10       Impact factor: 4.927

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.